Amongst the genes down-regulated by miR-34a, we selected five genes (ATM, EGFR, BCL2, MET, UGCG) for validation as they have been shown pre-clinically to play critical roles in cell survival and therapeutic resistance in the context of glioblastoma (Eich et al. 2013; Munoz et al. 2014; Barvaux et al. 2004; Jun et al. 2007; Giussani et al. 2012). The gene discussed is MET; the disease is glioblastoma.